search
Back to results

Lymphangioleiomyomatosis (LAM) Registry

Primary Purpose

Lung Diseases, Lymphangiomyomatosis

Status
Completed
Phase
Locations
Study Type
Observational
Intervention
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Lung Diseases

Eligibility Criteria

undefined - 100 Years (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

No eligibility criteria

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    May 25, 2000
    Last Updated
    February 17, 2016
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00005486
    Brief Title
    Lymphangioleiomyomatosis (LAM) Registry
    Study Type
    Observational

    2. Study Status

    Record Verification Date
    December 2005
    Overall Recruitment Status
    Completed
    Study Start Date
    July 1997 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    June 2003 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    5. Study Description

    Brief Summary
    To establish a registry of individuals with LAM by forming a consortium of six clinical centers and referring physicians who treat LAM patients.
    Detailed Description
    BACKGROUND: LAM is a rare multi-system disease that can affect the lungs of young women, is of uncertain cause, is usually progressive, and can cause debilitating lung disease which may be corrected with lung transplantation. Several hundred women with the disease have been identified, largely through a LAM Foundation in Cincinnati, Ohio. DESIGN NARRATIVE: The Data and Coordinating Center is located at the Cleveland Clinic Foundation. The registry has six major clinical centers: Cleveland Clinic Foundation, Mayo Clinic-Rochester, National Heart, Lung, and Blood Institute, National Jewish Medical and Research Center, New England Medical Center, and Stanford University Medical Center. Data and lung tissue collected by the registry will be used to characterize the clinical features and natural history of the disease and to determine the efficacy of lung transplantation in this disorder. Eligible patients are to be seen yearly for up to 4 years at the Clinical Centers or, in some cases, by individual referring physicians. Tissue collected by the LAM Registry will be stored at a central NHLBI repository. Outcome events include measures of pulmonary function (eg, spirometry and, when available, lung volumes and diffusing capacity), arterial blood gases or oximetry, walking and resting oxygen titration, cardiopulmonary stress testing, cause-specific mortality, functional status, and clinical events associated with lung transplantation. The Office of Research on Women's Health provided funding in FY 1997 in the amount of $100,000. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lung Diseases, Lymphangiomyomatosis

    7. Study Design

    10. Eligibility

    Sex
    Female
    Maximum Age & Unit of Time
    100 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    No eligibility criteria
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gerald Beck
    Organizational Affiliation
    The Cleveland Clinic

    12. IPD Sharing Statement

    Citations:
    Citation
    Sullivan EJ, Stoller JK. The registry for individuals with lymphangioleiomyomatosis. In J. Moss, editor. LAM and Other Diseases Characterized by Smooth Muscle Proliferation. Marcel Dekker, New York, NY, pp 99-110, 1998.
    Results Reference
    background
    PubMed Identifier
    9925106
    Citation
    Sullivan EJ, Beck GJ, Peavy HH, Fanburg BL. Lymphangioleiomyomatosis Registry. Chest. 1999 Jan;115(1):301. doi: 10.1378/chest.115.1.301. No abstract available.
    Results Reference
    background
    PubMed Identifier
    9872207
    Citation
    Sullivan EJ. Lymphangioleiomyomatosis: a review. Chest. 1998 Dec;114(6):1689-703. doi: 10.1378/chest.114.6.1689. No abstract available.
    Results Reference
    background
    PubMed Identifier
    16210669
    Citation
    Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006 Jan 1;173(1):105-11. doi: 10.1164/rccm.200409-1298OC. Epub 2005 Oct 6.
    Results Reference
    background

    Learn more about this trial

    Lymphangioleiomyomatosis (LAM) Registry

    We'll reach out to this number within 24 hrs